Salinomycin sodium salt
Based on 52 publication(s) in Google Scholar
Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of Wnt/β-catenin signaling. Salinomycin sodium salt acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt shows selective activity against human cancer stem cells.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.81%
- No. CAS: 55721-31-8
- Fòrmula: C42H69NaO11
- Peso molecular:772.98
-
Almacenamiento:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Salinomycin sodium salt
More- Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]
- Adv Sci (Weinh). 2025 Sep 9:e13476. [Abstract]
- Adv Sci (Weinh). 2025 Apr;12(13):e2415229. [Abstract]
- J Control Release. 2020 Oct 10:326:387-395. [Abstract]
- Cell Death Dis. 2023 Mar 11;14(3):193. [Abstract]
- Pharmacol Res. 2020 May:155:104751. [Abstract]
- Biosens Bioelectron. 2024 Jul 1:255:116245. [Abstract]
- Cell Commun Signal. 2018 Nov 23;16(1):89. [Abstract]
- Acta Biomater. 2022 Oct 15:152:380-392. [Abstract]
- Int J Nanomedicine. 2020 Sep 15:15:6839-6854. [Abstract]
- Int J Mol Med. 2019 Oct;44(4):1289-1298. [Abstract]
- Mol Med. 2025 Jan 22;31(1):19. [Abstract]
- EMBO Mol Med. 2019 Oct;11(10):e9930. [Abstract]
- Cell Rep. 2025 Jul 22;44(7):115922. [Abstract]
- Anal Chem. 2023 Apr 11;95(14):6191. [Abstract]
- Talanta. 2025 Oct 1:293:128128. [Abstract]
- Eur J Med Chem. 2024 Oct 5:276:116701. [Abstract]
- Cell Biosci. 2021 Aug 4;11(1):156. [Abstract]
- Biomed J. 2020 Aug;43(4):368-374. [Abstract]
- RSC Adv. 2021 Nov 2;11(56):35331-35341. [Abstract]
- J Mol Cell Biol. 2025 Dec 2:mjaf048. [Abstract]
- Hepatol Commun. 2025 May 16;9(6):e0706. [Abstract]
- Int J Pharm. 2023 Mar 25:635:122779. [Abstract]
- Eur J Pharmacol. 2025 Jul 5:998:177533. [Abstract]
- Cell Oncol (Dordr). 2024 Dec;47(6):2201-2215. [Abstract]
- Int J Mol Sci. 2023 Mar 21;24(6):5939. [Abstract]
- Int J Mol Sci. 2019 Jun 12;20(12):2861. [Abstract]
- Nanoscale. 2024 Nov 7;16(43):20131-20146. [Abstract]
- AAPS PharmSciTech. 2024 Sep 7;25(7):211. [Abstract]
- Sci Rep. 2026 Feb 9;16(1):7909. [Abstract]
- Cancers (Basel). 2020 Aug 5;12(8):2176. [Abstract]
- Oncol Rep. 2018 Aug;40(2):877-886. [Abstract]
- ACS Infect Dis. 2021 Aug 13;7(8):2390-2401. [Abstract]
- Antiviral Res. 2026 May:249:106403. [Abstract]
- FASEB J. 2025 Dec 31;39(24):e71350. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2025 Aug;1872(6):119989. [Abstract]
- Viruses. 2022 Aug 6;14(8):1734. [Abstract]
- J Bioenerg Biomembr. 2021 Oct;53(5):513-523. [Abstract]
- Int J Hyperthermia. 2026 Dec;43(1):2643510. [Abstract]
- Exp Ther Med. 2020 Mar;19(3):1835-1843. [Abstract]
- Leuk Lymphoma. 2023 Jun;64(6):1151-1160. [Abstract]
- Res Sq. 2026 Jan 9.
- SSRN. 2025 Dec 2.
- SSRN. 2024 Nov 12.
- bioRxiv. 2024 September 18.
- bioRxiv. 2024 September 07.
- Chemosphere. 2024 Aug:362:142758. [Abstract]
- bioRxiv. 2023 Jun 25.
- bioRxiv. 2023 Jan 17.
- Research Square Print. 2023 Jan 6th.
- Norwegian University of Science and Technology. 2021 Oct.
- bioRxiv. 2020 Jun.
Customer Validation & Images
-
Others
-
WB
-
WB
-
WB
Ver todos los productos específicos de isoformas Antibiotic
MoreVer todos los productos específicos de isoformas Parasite
More
Actividad biológica
Wnt/β-catenin[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
0.002 μM
Compound: 92124650
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
|
[PMID: 22586124] |
| HepG2 | IC50 |
58 μM
Compound: 92124650
|
HARVARD: Cytotoxicity in HepG2 cell line
HARVARD: Cytotoxicity in HepG2 cell line
|
[PMID: 22586124] |
| MCF7 | IC50 |
0.59 μM
Compound: 74
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 30684870] |
Salinomycin (0.1-8 μM; 48 h) inhibits the growth of HUVECs in a dose-dependent manner, accounting for 32.1 and 59.2% inhibition at 4 and 8 μM, respectively. HUVECs exposed to 2, 4 and 8 μM of Salinomycin for 48 h show a dose-dependent reduction in cell number and a change in cell morphology. Salinomycin (4 μM) treatment effectively inhibits HUVEC migration and invasion, and significantly disrupt the capillary-like tube formation of HUVECs. Salinomycin significantly suppresses the expression levels of phosphorylated (p)-FAK in a time- and dose-dependent manner in HUVECs. Salinomycin inhibits HUVEC angiogenesis by disturbing the VEGF-VEGFR2-AKT signaling axis[1].
Combination of RSVL and Salinomycin synergistically inhibits the proliferation of TNBC (MDA-MB-231) cells. RSVL and Salinomycin effectively reduce wound healing, colony and tumorosphere forming capability in TNBC cells. Synergistic combination of RSVL and Salinomycin induces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2 expression as comparison to untreated and alone drug treatments[2]. Salinomycin (0, 2, 4, 8 and 16 μM) significantly inhibits the proliferation of A2780 and SK-OV-3 cell lines in a dose- and time-dependent manner, (IC50 24h: 13.8 μM, IC50 48h: 6.888 μM and IC50 72h: 4.382 μM for A2780 cell lines), (IC50 24h: 12.7 μM, IC50 48h: 9.869 μM and IC50 72h: 5.022 μM for SK-OV-3 cell lines). Salinomycin blocks the Wnt/β-catenin pathway in EOC cells[3]. Salinomycin (2 μM) reduces cancer cell proliferation, inhibits STAT3 phosphorylation and P38 and β-catenin expressions, and suppresses epithelial-mesenchymal transition in colorectal cancer cells. Salinomycin (1-5 μM) inhibits cancer cell proliferation and STAT3 signaling in colorectal cancer cells. Furthermore, Salinomycin activates Akt (Ser 473) and down-regulates Hsp27 (Ser 82) phosphorylation in HT-29 and SW480. Salinomycin down-regulates hTERT and reduces telomerase activity when combined with telomerase inhibitor[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 55721-31-8
-
Appearance Solid
-
Peso molecular 772.98
-
Fòrmula C42H69NaO11
-
Color White to yellow
-
SMILES
[H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O[Na])=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1
-
Synonyms
Salinomycin sodium; Sodium salinomycin
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (52)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Jul 18;16(1):6621. PMID: 40681515
Salinomycin sodium salt purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]
Salinomycin sodium salt (20 μM). The formation of membrane-like structures of GFP-ATG8a in response to three ionophores.
-
Adv Sci (Weinh)
Targeting Fibrotic Scarring by Mechanoregulation of Il11ra1+/Itga11+ Fibroblast Patterning Promotes Axon Growth after Spinal Cord Injury. [Abstract]2025 Sep 9:e13476. PMID: 40923460 -
Adv Sci (Weinh)
A Novel tRF, HCETSR, Derived From tRNA-Glu/TTC, Inhibits HCC Malignancy by Regulating the SPBTN1-catenin Complex Axis. [Abstract]2025 Apr;12(13):e2415229. PMID: 39921434 -
J Control Release
2020 Oct 10:326:387-395. PMID: 32702392 -
Cell Death Dis
PDIA4 confers resistance to ferroptosis via induction of ATF4/SLC7A11 in renal cell carcinoma. [Abstract]2023 Mar 11;14(3):193. PMID: 36906674 -
Pharmacol Res
Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]2020 May:155:104751. PMID: 32151678 -
Biosens Bioelectron
Proximity labeling-assisted click conjugation for electrochemical analysis of specific subpopulations in circulating extracellular vesicles. [Abstract]2024 Jul 1:255:116245. PMID: 38555770 -
Cell Commun Signal
M2 macrophages promote myofibroblast differentiation of LR-MSCs and are associated with pulmonary fibrogenesis. [Abstract]2018 Nov 23;16(1):89. PMID: 30470231
Salinomycin sodium salt purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2018 Nov 23;16(1):89. [Abstract]
The expression of collagen I, α-smooth muscle actin (α-SMA), and Sca-1 in lung tissues is measured by western blotting in the treatment of Saline, Salinomycin, Bleomycin+Vehicle, and Bleomycin+ Salinomycin.
-
Acta Biomater
Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy. [Abstract]2022 Oct 15:152:380-392. PMID: 36028199 -
Int J Nanomedicine
Salinomycin-Loaded Small-Molecule Nanoprodrugs Enhance Anticancer Activity in Hepatocellular Carcinoma. [Abstract]2020 Sep 15:15:6839-6854. PMID: 32982236 -
Int J Mol Med
Simvastatin promotes endothelial dysfunction by activating the Wnt/β‑catenin pathway under oxidative stress. [Abstract]2019 Oct;44(4):1289-1298. PMID: 31432100 -
Mol Med
The mechanism of enterogenous toxin methylmalonic acid aggravating calcium-phosphorus metabolic disorder in uremic rats by regulating the Wnt/β-catenin pathway. [Abstract]2025 Jan 22;31(1):19. PMID: 39844078 -
EMBO Mol Med
A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. [Abstract]2019 Oct;11(10):e9930. PMID: 31476112 -
Cell Rep
Controlling mitochondrial membrane architecture via MIC60 determines viral replication to promote anti-viral immunity. [Abstract]2025 Jul 22;44(7):115922. PMID: 40628273 -
Anal Chem
Label-Free Isolation of Low-Adhesion Cells with Stem Properties for Cancer Stem Cell-Specific Drug Evaluation. [Abstract]2023 Apr 11;95(14):6191. PMID: 36122350 -
Talanta
Fluorescence-activated cell sorting-based efficient screening of monensin monoclonal antibodies and applications in lateral flow immunoassay. [Abstract]2025 Oct 1:293:128128. PMID: 40222095 -
Eur J Med Chem
A peptide-salinomycin conjugate with a bystander effect reduces the stemness characteristics of ovarian cancer cells and enhances drug sensitivity. [Abstract]2024 Oct 5:276:116701. PMID: 39067438 -
Cell Biosci
Modaline sulfate promotes Oct4 expression and maintains self-renewal and pluripotency of stem cells through JAK/STAT3 and Wnt signaling pathways. [Abstract]2021 Aug 4;11(1):156. PMID: 34348786
Salinomycin sodium salt purchased from MedChemExpress. Usage Cited in: Cell Biosci. 2021 Aug 4;11(1):156. [Abstract]
Salinomycin (0.0078125 μg/ml; for 24 h) reverses the MDLS-induced up-regulation of Oct4. The expression of Oct4 is determined using Western blot analysis.
-
Biomed J
2020 Aug;43(4):368-374. PMID: 32563698 -
RSC Adv
BSA-MnO2-SAL multifunctional nanoparticle-mediated M1 macrophages polarization for glioblastoma therapy. [Abstract]2021 Nov 2;11(56):35331-35341. PMID: 35493189 -
J Mol Cell Biol
The inwardly rectifying potassium channel KCNJ12 regulates the stemness of hepatocellular carcinoma cells through the Wnt/β-catenin pathway. [Abstract]2025 Dec 2:mjaf048. PMID: 41328864 -
Hepatol Commun
Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening. [Abstract]2025 May 16;9(6):e0706. PMID: 40377490 -
Int J Pharm
Polylactic Acid Based Biodegradable Hybrid Block Copolymeric Nanoparticle Mediated Co-delivery of Salinomycin and Doxorubicin for Cancer Therapy. [Abstract]2023 Mar 25:635:122779. PMID: 36842520 -
Eur J Pharmacol
To explore the potential combined treatment strategy for colorectal cancer: Inhibition of cancer stem cells and enhancement of intestinal immune microenvironment. [Abstract]2025 Jul 5:998:177533. PMID: 40120791 -
Cell Oncol (Dordr)
Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFβ and Hedgehog signal pathway. [Abstract]2024 Dec;47(6):2201-2215. PMID: 39373858 -
Int J Mol Sci
2023 Mar 21;24(6):5939. PMID: 36983012 -
Int J Mol Sci
Sphingomyelin Synthase 2 Promotes Endothelial Dysfunction by Inducing Endoplasmic Reticulum Stress. [Abstract]2019 Jun 12;20(12):2861. PMID: 31212751 -
Nanoscale
Folic acid-targeted redox responsive polylactic acid-based nanoparticles co-delivering pirarubicin and salinomycin suppress breast cancer tumor growth in vivo. [Abstract]2024 Nov 7;16(43):20131-20146. PMID: 39420738 -
AAPS PharmSciTech
Concomitant Delivery of Pirarubicin and Salinomycin Synergistically Enhanced the Efficacy of Cancer Therapy and Reduced the Risk of Cancer Relapse. [Abstract]2024 Sep 7;25(7):211. PMID: 39242397 -
Sci Rep
PFDN2 stabilizes PYCR2 to activate Wnt/β-catenin signaling and promote colorectal cancer progression. [Abstract]2026 Feb 9;16(1):7909. PMID: 41656306 -
Cancers (Basel)
Physical Cues in the Microenvironment Regulate Stemness-Dependent Homing of Breast Cancer Cells. [Abstract]2020 Aug 5;12(8):2176. PMID: 32764400 -
Oncol Rep
Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells. [Abstract]2018 Aug;40(2):877-886. PMID: 29989650
Salinomycin sodium salt purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Aug;40(2):877-886. [Abstract]
Salinomycin (SAL) has a pro-apoptotic effect on NB4 and HL-60 cells. The apoptosis-related protein levels of Bax and Bcl-2 are assessed by western blotting with the β-actin protein as an internal control.
-
ACS Infect Dis
Ex Vivo Phenotypic Screening of Two Small Repurposing Drug Collections Identifies Nifuratel as a Potential New Treatment against Visceral and Cutaneous Leishmaniasis. [Abstract]2021 Aug 13;7(8):2390-2401. PMID: 34114790 -
Antiviral Res
Salinomycin inhibits orthopoxvirus infection in vitro and in vivo by blocking endosomal acidification. [Abstract]2026 May:249:106403. PMID: 41941992 -
FASEB J
Stem Cells From the Apical Papilla Cultured in Spheroids Spontaneously Differentiate Into Odontoblasts via N-Cadherin Downregulation. [Abstract]2025 Dec 31;39(24):e71350. PMID: 41399894 -
Biochim Biophys Acta Mol Cell Res
Salinomycin inhibits SREBP1 to sensitize ferroptosis and ameliorate sorafenib resistance in clear cell renal cell carcinoma. [Abstract]2025 Aug;1872(6):119989. PMID: 40360020 -
Viruses
2022 Aug 6;14(8):1734. PMID: 36016355 -
J Bioenerg Biomembr
Pre-clinical evidence that salinomycin is active against retinoblastoma via inducing mitochondrial dysfunction, oxidative damage and AMPK activation. [Abstract]2021 Oct;53(5):513-523. PMID: 34365583 -
Int J Hyperthermia
Eliminating cancer stem cells can inhibit progression of residual hepatocellular carcinoma after radiofrequency ablation. [Abstract]2026 Dec;43(1):2643510. PMID: 41883111 -
Exp Ther Med
Synthesis of chemical tools to improve water solubility and promote the delivery of salinomycin to cancer cells. [Abstract]2020 Mar;19(3):1835-1843. PMID: 32104239 -
Leuk Lymphoma
Salinomycin sodium exerts anti diffuse large B-cell lymphoma activity through inhibition of LRP6-mediated Wnt/β-catenin and mTORC1 signaling. [Abstract]2023 Jun;64(6):1151-1160. PMID: 37092573 -
-
-
-
-
-
Chemosphere
PFDA promotes cancer metastasis through macrophage M2 polarization mediated by Wnt/β-catenin signaling. [Abstract]2024 Aug:362:142758. PMID: 38969224 -
-
-
-
-
Solvente y solubilidad
DMSO : 100 mg/mL (129.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
The effect of Salinomycin on HUVEC growth is determined by MTT assay. Briefly, HUVECs (6,000 cells/well) are seeded in 96-well culture plates for 24 h and incubated with different concentrations of Salinomycin. In the preliminary experiments, Salinomycin treatment for 12, 24, 48 and 72 h shows time-dependent effects on cell growth inhibition. However, treatment for 48 h is the optimal time and is selected for further mechanism evaluation. After Salinomycin treatment for 48 h, 20 µL/well of MTT solution (5 mg/mL) is added and incubated for 5 h. The medium is aspirated and replaced with 200 µL/well of DMSO to dissolve the formazan Salinomycint formed. The color intensity of the formazan solution is measured at 570 nm by a microplate spectrophotometer. The cell viability is expressed as % of the control (as 100%).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Human glioma U251 cells (1×107) suspended in 100 µL PBS are injected into the right lower hind flank of each 6-week-old male nude mouse. The mice are then randomly assigned into three groups of 10 mice in each group. After one week, Salinomycin (5 and 10 mg/kg) is administered into the caudal vein every other day for 16 days. Control mice receive an equal volume of vehicle (Salinomycinine) only. Body weight and tumor volume are monitored every two days. At the end of the experiments, tumors are excised, photographed, and weighed. Tumors from each group are used for western blotting and immunohistochemical (IHC) assay.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (284 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Lu D, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7. [Content Brief]
[2]. Zhou J, et al. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactiveoxygen species. Toxicol Lett. 2013 Oct 24;222(2):139-45. [Content Brief]
[3]. Klose J, et al. Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS One. 2019 Feb 14;14(2):e0211916. [Content Brief]
[4]. Wang F, et al. Salinomycin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells In Vitro and In Vivo. PLoS One. 2012; 7(12): e50638. [Content Brief]
[5]. Qu H, et al. Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med. 2015 Jul;8(7):578-82. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2937 mL | 6.4685 mL | 12.9369 mL | 32.3424 mL |
| 5 mM | 0.2587 mL | 1.2937 mL | 2.5874 mL | 6.4685 mL | |
| 10 mM | 0.1294 mL | 0.6468 mL | 1.2937 mL | 3.2342 mL | |
| 15 mM | 0.0862 mL | 0.4312 mL | 0.8625 mL | 2.1562 mL | |
| 20 mM | 0.0647 mL | 0.3234 mL | 0.6468 mL | 1.6171 mL | |
| 25 mM | 0.0517 mL | 0.2587 mL | 0.5175 mL | 1.2937 mL | |
| 30 mM | 0.0431 mL | 0.2156 mL | 0.4312 mL | 1.0781 mL | |
| 40 mM | 0.0323 mL | 0.1617 mL | 0.3234 mL | 0.8086 mL | |
| 50 mM | 0.0259 mL | 0.1294 mL | 0.2587 mL | 0.6468 mL | |
| 60 mM | 0.0216 mL | 0.1078 mL | 0.2156 mL | 0.5390 mL | |
| 80 mM | 0.0162 mL | 0.0809 mL | 0.1617 mL | 0.4043 mL | |
| 100 mM | 0.0129 mL | 0.0647 mL | 0.1294 mL | 0.3234 mL |
Salinomycin sodium salt Related Classifications
HY-17439 Related Classifications
Powered by Bioz